STOCK TITAN

Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Dianthus Therapeutics, Inc. has a significant shareholder group led by Wellington Management entities, which report passive beneficial ownership of its common stock. Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP collectively report beneficial ownership of 3,229,882 shares of common stock, representing approximately 5.9–5.91% of the class.

These shares are held of record by clients of various Wellington investment advisers. The Wellington filers report 0 shares with sole voting or dispositive power, and only shared voting and dispositive power over the reported shares. No individual client is reported to have rights over more than five percent of the class.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 3,229,882 shares Beneficial ownership reported by Wellington entities in Schedule 13G
Percent of class (Item 4(b)) 5.91 % Overall percent of Dianthus common stock class reported as beneficially owned
Percent of class (cover pages) 5.9 % Percent of class shown on individual Wellington cover pages
Shared voting power 2,795,605 shares Maximum number of shares over which Wellington reports shared voting power
Shared dispositive power 3,229,882 shares Maximum number of shares over which Wellington reports shared dispositive power
CUSIP 252828108 CUSIP number for Dianthus Therapeutics common stock
beneficially owned financial
"Amount beneficially owned: See the responses to Item 9 on the attached cover pages."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 2,795,605.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 3,229,882.00"
parent holding company financial
"Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company"
investment advisers financial
"The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers"

FAQ

What percentage of Dianthus Therapeutics (DNTH) shares does Wellington report owning?

Wellington-affiliated entities report beneficial ownership of about 5.9–5.91% of Dianthus Therapeutics’ common stock. This stake is held through clients of Wellington investment advisers, which own the shares of record while Wellington reports shared voting and dispositive power.

How many Dianthus Therapeutics (DNTH) shares are reported by Wellington entities?

Wellington entities report beneficial ownership of 3,229,882 shares of Dianthus Therapeutics common stock. These shares are owned of record by advisory clients of one or more Wellington investment advisers, with Wellington reporting shared voting and dispositive powers over them.

Does Wellington have sole voting power over Dianthus Therapeutics (DNTH) shares?

Wellington entities report 0 shares with sole voting power in Dianthus Therapeutics. Instead, they disclose shared voting power over up to 2,795,605 shares, with the shares held of record by advisory clients rather than by Wellington itself.

What dispositive power does Wellington report over Dianthus Therapeutics (DNTH) stock?

Wellington reports no sole dispositive power and shared dispositive power over up to 3,229,882 shares of Dianthus Therapeutics. This means decisions to sell or otherwise dispose of these shares are made on a shared basis for clients of its investment advisers.

Are any single Wellington clients over 5% in Dianthus Therapeutics (DNTH)?

No. The filing states that no individual client of the Wellington investment advisers is known to have the right to receive dividends or sale proceeds for more than five percent of Dianthus Therapeutics’ common stock class.

Which Wellington entities are listed as reporting persons for Dianthus Therapeutics (DNTH)?

The reporting persons are Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP. They file as a parent holding and investment-adviser group with shared beneficial ownership over DNTH shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





252828108

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Group Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Investment Advisors Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026
Wellington Management Company LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:08/14/2026